A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT05496374 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Interventions

DRUG: Placebo
DRUG: SPR720 500 mg
DRUG: SPR720 1000 mg

Sponsor

Spero Therapeutics